

**Title:** Pulmonary complications for women with sickle cell disease in pregnancy: systematic review and meta-analysis

## **Authors**

### Corresponding Author

- Sivarajini Inparaj BSc (Hons), Medical student, King's College London, London, UK
- Address: 28 Brook Close, Plymouth, PL7 1JR United Kingdom
- Telephone: 07734330469

### Co-Authors

- Mickey Buckingham BM BCh, Specialty trainee in Obstetrics and Gynaecology, Guy's and St Thomas' NHS Foundation Trust, London, UK
- Laura Oakley PhD Assistant Professor, Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK  
Researcher, Centre for Fertility and Health, Norwegian Institute of Public Health, PO Box 4404 Nydalen, N-0403 Oslo, Norway
- Paul T Seed, MSc CStat, Senior Lecturer in Medical Statistics, King's College London, London, UK
- Sebastian Lucas FRCP FRCPath, Emeritus Professor of Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK
- Eugene Oteng-Ntim MBBS MRCOG PGDip FRCOG, Consultant Obstetrician, Guy's and St Thomas' NHS Foundation Trust, London, UK

## **Abstract**

**Background:** Sickle cell disease (SCD) is a multi-system disease characterised by vaso-occlusive crisis, chronic anaemia and a shorter lifespan. More patients with SCD are living till reproductive age and contemplating pregnancy. Pulmonary complications in pregnancy are significant causes of maternal morbidity and mortality but yet this has not been systematically quantified. A systematic review and meta-analysis were conducted to quantify the association between SCD and pulmonary complications in pregnancy.

**Methods:** MEDLINE, EMBASE, Web of Science, Cochrane and Maternity and Infant Care databases were searched for publications between January 1998 and April 2019. Observational studies involving at least 30 participants were included. Random effects models were used for statistical meta-analysis. The study was registered a priori with Prospero CRD42019124708.

**Findings:** Twenty-two studies were included in the systematic review and eighteen in the quantitative analysis. The meta-analysis included 3964 pregnancies with SCD and 336559 controls. Compared with women without SCD, pregnancies complicated by SCD were at increased risk of pulmonary thromboembolism (RR 7.74; 95% CI, 4.65-12.89). The estimated prevalence of ACS and pneumonia was 6.46% (95% CI, 4.66%-8.25%), with no significant difference between the HbSS and HbSC genotypes (RR, 1.42; 95% CI, 0.90-2.23).

**Interpretation:** This meta-analysis highlighted a strong association between SCD and maternal pulmonary complications. Understanding the risks of and the factors associated with pulmonary complications would aid pre-conceptual counselling and optimal management of the condition in pregnancy, thereby reducing associated maternal morbidity and mortality.

## **Key Messages**

### **What is the key question?**

To what extent are pregnant women with sickle cell disease at increased risks of pulmonary complications?

### **What is the bottom line?**

Pregnancies with sickle cell disease are associated with an almost eight-fold increased risk of pulmonary thromboembolism and a prevalence of 6.5% for acute chest syndrome and pneumonia.

### **Why read on?**

Understanding the risks of and the factors associated with pulmonary complications would aid pre-conceptual counselling and optimal management of the condition, thereby reducing associated morbidity and mortality.

## **INTRODUCTION**

Sickle cell disease (SCD), as an autosomal recessive hemoglobinopathy, is a devastating multi-organ disease characterised by vaso-occlusive crises and chronic anaemia [1]. It is one of the most common genetic disorders globally with over 300,000 children born with the condition each year [2]. The life expectancy is reduced for people with SCD [3]. With the introduction of neonatal screening for SCD and the increased awareness of the importance of antibiotic prophylaxis and multi-disciplinary management, more women are living till reproductive age and contemplating pregnancy [4]. In the UK, there are approximately 100-200 pregnancies in women with SCD per year [5]. Pregnancies complicated by SCD are associated with increased risk of adverse maternal and perinatal outcomes [6,7]

Individual studies have shown that pregnant women with SCD are at increased risk of pulmonary complications. In particular, pulmonary complications including acute chest syndrome (ACS), pneumonia, pulmonary thromboembolism (PTE) and pulmonary hypertension (PH) are significant causes of maternal morbidity and mortality [8]. However, the heterogeneity inherent with the disease expression of SCD and with the setting of these studies leads to uncertainty when estimating the associated risks [9]. The lack of comprehensive data on pulmonary complications for pregnant women with SCD has led to difficulties in pre-conceptual and antenatal counselling as well as clinical care pathways. The aim of this study is to systematically review and meta-analyse the risks of pulmonary complications in pregnancies complicated by SCD compared to pregnancies without SCD. In addition, we aim to evaluate whether the risk is greater for HbSS genotype compared to HbSC genotype, and to identify the proportion of maternal mortality associated with pulmonary complications.

## **METHODS**

### **Search strategy**

A systematic review and meta-analysis were performed according to the Meta-analysis of Observation Studies in Epidemiology (MOOSE) group criteria and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [10]. The following databases were searched for articles published between 20th Jan 1998 and 15th March 2019 for titles and abstracts related to our research question: MEDLINE via Ovid, EMBASE, Cochrane, Web of Science, Maternity and Infant Care. Abstracts and full-text articles were reviewed by two assessors (S.I. and M.B.) independently and results were compared. In

addition, we cross-examined references from relevant original papers and reviewed articles to identify further relevant studies. This systematic review and meta-analysis were limited to English language articles. The study was registered a priori with Prospero CRD42019124708.

### **Study selection**

Studies were included in the systematic review if they met the following criteria: the study design was observational; the exposure of interest was SCD in pregnancy; pulmonary complications were reported and a minimum of thirty pregnant women with SCD were included as smaller studies tend to be of variable quality and add very little to the findings. We excluded animal studies, conference abstracts and manuscripts relating to sickle cell trait only.

### **Data Extraction**

Data extraction was carried out independently by the two assessors using a standard extraction form. Two assessors undertook the screening for papers, read full-texts and assessed the final selection of papers. In the case of disagreement, a third assessor was consulted. The following information from each study was extracted: authors; year of publication; study name; study design; country of study, study setting, number of participants, relevant outcomes on pulmonary complications including ACS, PTE, pneumonia, PH and maternal mortality secondary to pulmonary complications. We obtained the gross national income per capita for each study location from World Bank data.

### **Quality Assessment**

The Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the papers [11]. The studies were evaluated with regards to three aspects: selection of the study groups, comparability of the groups and assessment of outcome, with a total of 9 stars available. The studies were categorised as high (7-9), medium (4-6) or low grade (1-3).(Table S2)

### **Statistical analysis**

Analyses were pregnancy based. The main measure of effect of maternal SCD on pulmonary complications during pregnancy was the unadjusted risk ratio, calculated from the given numbers of pregnancies and events. We undertook separate comparisons for women with HbSS and HbSC genotypes, as well as for pregnancies managed in high-income and low- and middle-income settings, for the prevalence of ACS and pneumonia. Depending on the outcome under consideration, studies with no events in either arm were excluded. To assess the association of

each pulmonary complication in pregnancy for women with SCD, random effects models were used for statistical meta-analysis [12]. Heterogeneity of the studies was tested with the Breslow-Day test to measure inconsistency [13]. The level of heterogeneity was expressed as  $I^2$ . An  $I^2$  score  $> 50\%$  was agreed to indicate high heterogeneity. Publication bias (due to the non-publication of small, non-significant studies) was not relevant in discussing prevalence study as significance tests were not used. For PTE, there were too few studies ( $n=2$ ) for a formal test. Based on the results obtained from the funnel plots, we used random effects model. We have used the continuity correction of a 0.5 when there were zero events. Stata version 15.1 was used for all statistical analyses.

## **RESULTS**

A flowchart for identification of papers and subsequent evaluations is shown in Figure 1. After the exclusion of ineligible papers, twenty-two papers were included for narrative review and eighteen papers for quantitative analysis.

**Figure 1.** Flowchart of study selection

### **Study Characteristics**

The characteristics of the studies included in the systematic review and meta-analysis are outlined in Table S1 [14-35].

Of the twenty-two studies included in the systematic review, four studies were prospective cohort studies, seventeen retrospective and one was both retrospective and prospective. Thirteen studies were from high-income countries (HIC) and nine were from low- or medium-income countries (LMIC). Seven studies were considered to be of high quality and fifteen of medium quality (Table S2). The meta-analysis included 3964 pregnancies with SCD and 336559 pregnancies without SCD. Of the twenty-two studies, eleven used pregnant women with normal hemoglobin (HbAA) as a control group and eleven studies did not include a control group.

### **Prevalence of ACS and pneumonia in pregnant women with SCD**

Eighteen studies evaluated outcomes of ACS and pneumonia. Regarding the clinical case definition of ACS, four studies [20,26,30,32] applied the standard of new pulmonary signs/symptoms accompanied by new pulmonary infiltrates on chest X ray [36]; the other ten

studies did not state a formal case definition. We have taken this into account when assessing the quality of the studies using the NOS scale [11]. In view of the difficulty in distinguishing ACS from pneumonia clinically, we have chosen to evaluate ACS/pneumonia as a combined outcome when assessing its prevalence.

There was a strong evidence of heterogeneity ( $I^2=89.29\%$ ). The funnel plot (figure 2) showed that the larger studies tended to have much smaller event rates. Studies with event rates under 5% were typically larger (mean size 383, compared to 90), but identified fewer cases (mean 7.35, compared to 13.8). Because of this, some of the largest studies (Rajab et al [27] and Al Kahtani et al [17]) had bigger standard error and less accurate estimates (on the log scale) than smaller studies such as Silvia-Pinto et al [31], Soh et al [32] and Al-Farsi et al[14].

The meta-analysis and forest plot therefore considered event rates by sample size (Figure 3). The smaller studies ( $n < 100$  and  $n=100$  to  $150$ ) gave estimates of 15.04% [95% confidence interval (CI), 8.18 to 21.91] and 10.07% (95% CI, 3.48 to 16.66). For the six largest studies the estimate was 2.82% (95% CI, 1.33 to 4.31). The composite estimate was 6.46% (95% CI, 4.66 to 8.25). Even after allowing for sample size, there was considerable heterogeneity which we were unable to explain. There was no significant difference in the prevalence of ACS/pneumonia between the HbSS and HbSC genotypes [relative risk (RR), 1.42; 95% CI, 0.90 to 2.23] (Figure 4). LMIC (countries with a gross national income per capita of \$30,000 or less) had a higher prevalence of ACS/pneumonia (13.9%) compared to HIC (4.9%) ( $P=0.03$ ) (Figure 5).

**Figure 2** – Funnel plot of studies investigating the prevalence of ACS/Pneumonia in pregnant women with SCD, by sample size

**Figure 3** - Forest plot of studies investigating the prevalence of ACS/Pneumonia in pregnant women with SCD, by sample size

**Figure 4-** Forest plot of studies comparing the prevalence of ACS/Pneumonia in HbSS and HbSC genotype

**Figure 5-** Forest plot of studies investigating the prevalence of ACS/Pneumonia in high-income setting versus a low- middle- income setting.

## **Pulmonary thromboembolism**

Of the six studies that reported outcome on PTE, only two included a control group of women with HbAA. The estimated prevalence of PTE in women with SCD in pregnancy was 105/10,000 (95% CI, 65 to 170) and the estimated prevalence of PTE in women without SCD in pregnancy was 13.8/10,000 (95% CI, 12.5 to 15.1). There was nearly an eight-fold increased risk of PTE in women with SCD (RR 7.74; 95% CI, 4.65 to 12.89) (Figure 6).

**Figure 6** – Forest plot of studies investigating the association of SCD with PTE

## **Pulmonary Hypertension**

There was only one study that looked at PH in pregnancy for women with SCD [33]. This study reported a statistically significant increase in the occurrence of PH in pregnancies with SCD compared to pregnancies without SCD, with an odds ratio of 6.3 (95% CI, 2.1-18.8) [33]. An additional study investigated women with a tricuspid regurgitant velocity (TRV)>2.5m/s, however, it was acknowledged that TRV>2.5m/s has a high false positive rate and does not reliably predict pulmonary hypertension [32].

## **Maternal deaths due to pulmonary complications**

Six studies reported maternal deaths and overall 88% of the maternal deaths reported were secondary to pulmonary complications [16,18,20,27,29,31]. Four studies provided no evidence of any autopsies being done. The studies from Ghana [18] and Jamaica [29] stated some autopsy-derived pulmonary pathologies (see Table 1). The true pathological causes of death in the other reported instances were unknown (see Table S3 for a series with systematic autopsy pathology).

## **DISCUSSION**

This systematic review and meta-analysis identified a strong association between pregnancies with SCD and pulmonary complications, including ACS/pneumonia and PTE. In addition, pulmonary complications contributed substantially to maternal mortality in women with SCD. We believe this meta-analysis is the first review to provide pooled relative risks for pulmonary

complications in women with SCD in pregnancy, and to present prevalence estimates of ACS/pneumonia according to genotype. This review was strengthened by a comprehensive search strategy and a large pooled sample size of almost 4000 pregnancies with SCD. It remains a limitation that a small number of women contributed more than one pregnancy to an individual study. Without individual patient data, it was not possible to take this into account. In addition, comparisons between groups of women (e.g. ACS/pneumonia prevalence in women with HbSS and HbSC) were not adjusted for possible confounding factors such as maternal age and parity as individual patient data was not available.

The meta-analysis indicated that the prevalence of ACS/pneumonia is 6.46% for women with SCD during pregnancy. However, heterogeneity between studies was large, and the findings should be interpreted with caution. We acknowledge that ACS is a separate clinical entity to pneumonia with a different pathophysiology [36]. However, clinically the differentiation of ACS from other diagnoses, especially pneumonia, can often be challenging, and at times artificial. Therefore, we have reported ACS/pneumonia as a single outcome. Two studies observed that ACS occurred most frequently in the third trimester and early postpartum period [30,35], a finding that was also highlighted by a more recent study by Asare et al [37]. However, most included studies did not report on the timing of ACS therefore we were unable to stratify prevalence estimates by trimester.

ACS/pneumonia prevalence was higher in LMIC compared to HIC. This finding was consistent with two recent systematic reviews and meta-analyses which indicated significantly higher maternal mortality for pregnancies with SCD in LMIC compared to HIC [6,7]. These findings are likely to reflect variations in treatment pathways and standards of care across settings. One study from a HIC was unique in reporting a management pathway involving prophylactic exchange transfusions. This may have altered their reported outcomes on pulmonary complications [24], although the evidence regarding any beneficial impact of prophylactic transfusion is inconsistent [38] [39]. There is evidence that maternal mortality due to pulmonary complications can be reduced with a multi-disciplinary approach. In a low-resource setting in sub-Saharan Africa, implementing a multidisciplinary care strategy with a joint obstetric haematology clinic reduced maternal mortality by 89% in a pre- and post-intervention study, and a comparable mortality rates to women without SCD can be achieved [40,41]. In settings in which multidisciplinary care for this population is already well established, further research is needed to identify areas of improvement.

There was no statistically significant difference in the prevalence of ACS/pneumonia for women with HbSS genotype compared to HbSC genotype. This is in contrast to the general perception that HbSC is overall a clinically more benign phenotype than HbSS with regards to maternal and fetal complications [7]. The incidence of ACS in the general adult SCD population is known to be lower for adults with HbSC genotype (5.2 per 100 patient-years) when compared to HbSS genotype (12.8 per 100 patient-years) [42]. It may be that pregnancy is a specific process which heightens risk for women with HbSC. However, it should be noted that a small pooled sample size was used for the genotype-specific meta-analysis. In addition, some cases of HbSC might not be correctly depicted as HbSC. We note that two of the five studies included did not report on the method they used to distinguish the genotypes.

The high prevalence of ACS/pneumonia in women with SCD may relate to the increased susceptibility to infections during pregnancy. Early recognition and prompt management of respiratory infections may reduce painful crises [15] and ACS [8,43]. The eight-fold increased risk of pulmonary thromboembolism in pregnancy in women with SCD confirms the need for appropriate thromboprophylaxis, especially for women with other risk factors (RCOG guideline 2015) [44].

Women with SCD, particularly those with PH, should get pre-conceptual counselling about the risks associated with pregnancy. Earlier studies identified a maternal mortality of 56% in pregnant women with secondary vascular PH [45] and women with PH are often advised against pregnancy [46]. A key public health issue to highlight is provision of appropriate contraceptive advice for women with SCD of reproductive age. Progestogens and intrauterine devices are effective and safe methods. There are some concerns with the use of combined oral contraceptive pill in this group of women but there is no evidence confirming it increases risk of thrombosis [2,47].

Pulmonary complications contributed to the majority of maternal deaths, yet uncertainty remains regarding cause of death, particularly the pathogenesis of morbid complications in a disease where no diagnostic tissue pathology can be obtained in life. Complications including venous thromboembolism, amniotic fluid embolism, coagulopathy, PH, pneumonia, ACS and generalised sepsis can have overlapping clinical and imaging features (Table S3). Only a

comprehensive autopsy can provide a true diagnosis [8]; this does not take place in many countries where SCD is most prevalent.

Pregnant women with SCD are at high risk of pulmonary complications and associated mortality. This review and meta-analysis provides contemporary prevalence estimates of ACS/pneumonia and PTE in this population. This information can be used to aid pre-conceptual counselling and to inform optimal management of SCD in pregnancy by highlighting the need for timely identification of pulmonary complications in this population. Delay in initiation of treatments and escalation of care have previously been identified by the Confidential Enquiry into Maternal Deaths as contributing to maternal deaths [48]. Further adequately powered research is needed to understand why HbSC genotype may be at similar risks of developing ACS/pneumonia during pregnancy to HBSS genotype. In addition, there is a paucity of data on the incidence of PH in pregnancies with SCD and in particular the management of PH. More work is needed to reduce the pre-pregnancy morbidities and occurrence of PH in women with SCD and there is an urgent need for studies to address how best to improve management of care of women with PH should they wish to continue with pregnancy. The prevalence of SCD is increasing globally. This review and meta-analysis should encourage renewed efforts to improve the clinical management, and thereby reduce the severe morbidity and mortality, of pregnant women with sickle cell disease.

**Table 1 - Maternal deaths due to pulmonary complications of sickle cell disease**

<b>Study</b>	<b>Maternal deaths due to pulmonary complications</b>	<b>Total maternal deaths</b>
<b>Al Julfairi (2016) [16]</b>	2 due to PE, 1 due to ACS	4
<b>Asare (2018) [18]</b>	<ul style="list-style-type: none"> <li>• 8/44 deaths with autopsy report due to pulmonary embolism</li> <li>• 33/44 deaths due to a clinical diagnosis of ACS*</li> </ul>	44
<b>Cardoso (2014) [20]</b>	4	5
<b>Rajab (2006) [27]</b>	3	4
<b>Serjeant (2004) [29]</b>	1 autopsy-confirmed pneumonia and venous thromboembolism	2
<b>Silva-Pinto (2014) [31]</b>	1	1
<b>Total deaths</b>	53	60

\*Not all clinical diagnosis of ACS were subsequently confirmed on autopsy report.

ACS = acute chest syndrome

## **Acknowledgement**

none

## **Competing Interests**

None

## **Funding**

No funding received for this research

Paul T Seed is partly funded by Tommy's (Registered charity no. 1060508) and by CLAHRC South London (NIHR) as part of his employment

## **Contributorship statement**

This study was designed, directed and co-ordinated by EON and as the principal investigator, provided conceptual and technical guidance for all aspects of the project. SI and MB collected, analysed the data. PS performed the statistical analysis. The manuscript was written by SI and MB and commented on by all authors (LO, SL and EON).

## **REFERENCES**

1 Weatherall D. ABC of clinical haematology: The hereditary anaemias. *BMJ*1997;314:492-492. doi:10.1136/bmj.314.7079.492

2 Howard J, Oteng-Ntim E. The obstetric management of sickle cell disease. *Best Practice & Research Clinical Obstetrics & Gynaecology* 2012;26:25-36. doi:10.1016/j.bpobgyn.2011.10.001

3 Platt O, Brambilla D, Rosse W et al. Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early Death. *New England Journal of Medicine* 1994;330:1639-1644. doi:10.1056/nejm199406093302303

4 Streetly A, Sisodia R, Dick M et al. Evaluation of newborn sickle cell screening programme in England: 2010–2016. *Archives of Disease in Childhood* 2017;;archdischild-2017-313213. doi:10.1136/archdischild-2017-313213

5 Royal College of Obstetricians and Gynaecologists (2011) Management of sickle cell disease in pregnancy. Green top guideline No 61. 2019. [https://www.researchgate.net/publication/263052981\\_Royal\\_College\\_of\\_Obstetricians\\_and\\_Gynaecologists\\_guidelines\\_How\\_evidence-based\\_are\\_they](https://www.researchgate.net/publication/263052981_Royal_College_of_Obstetricians_and_Gynaecologists_guidelines_How_evidence-based_are_they) (accessed 27 Jun 2019).

6 Boafor T, Olayemi E, Galadanci N, Hayfron-Benjamin C, Dei-Adomakoh Y, Segbefia C et al. Pregnancy Outcomes in Women With Sickle-Cell Disease in Low and High Income Countries. *Obstetric Anesthesia Digest*. 2017;37(1):9-10. doi: 10.1097/01.aoa.0000511999.06517.f5

- 7 Oteng-Ntim E, Meeks D, Seed P et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. *Blood* 2015;125:3316-3325. doi:10.1182/blood-2014-11-607317
- 8 Guidelines on Autopsy Practice: Autopsy in sickle cell disease and persons with sickle cell trait. Royal College of Pathologists (London), April 2017. <https://www.rcpath.org/uploads/assets/27824659-5adc-4641-9824e08d6980443f/guidelines-on-autopsy-practice-autopsy-in-sickle-cell-disease-and-sickle-trait-persons.pdf> (accessed 20 Jun 2019).
- 9 Adekile A. What's New in the Pathophysiology of Sickle Cell Disease?. *Medical Principles and Practice* 2013;22:311-312. doi:10.1159/000350283
- 10 Stroup DF, Berlin JA, Mortin SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group *JAMA*. 2000;283(15) :2008-2012.
- 11 Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of non-randomised studies in meta-analyses, Available at: [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
- 12 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *Journal of the National Cancer Institute* 1959;22:719-48.
- 13 Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;21:1539-1558. doi:10.1002/sim.1186
- 14 Al-Farsi S, Al-Riyami N, Al-Khabori M et al. Maternal Complications and The Association with Baseline Variables in Pregnant Women with Sickle Cell Disease. *Hemoglobin*2013;37:219-226. doi:10.3109/03630269.2013.780249
- 15 Al Jama F, Gasem T, Burshaid S et al. Pregnancy outcome in patients with homozygous sickle cell disease in a university hospital, Eastern Saudi Arabia. *Archives of Gynecology and Obstetrics* 2009;280:793-797. doi:10.1007/s00404-009-1002-7
- 16 Al-Jufairi Z, Al-Arabi F, Sandhu A. Pregnancy Outcome of Sickle Cell Disease Women. *Bahrain Medical Bulletin* 2016;38:18-21. doi:10.12816/0047381
- 17 Al Kahtani M, AlQahtani M, Alshebaily M et al. Morbidity and pregnancy outcomes associated with sickle cell anemia among Saudi women. *International Journal of Gynecology & Obstetrics* 2012;119:224-226. doi:10.1016/j.ijgo.2012.07.008
18. Asare E, Olayemi E, Boafor T, Dei-Adomakoh Y, Mensah E, Osei-Bonsu Y et al. A case series describing causes of death in pregnant women with sickle cell disease in a low-resource setting. *American Journal of Hematology*. 2018;93(7):E167-E170. doi:10.1002/ajh.25115

- 19 Boulet S, Okoroh E, Azonobi I et al. Sickle Cell Disease in Pregnancy: Maternal Complications in a Medicaid-Enrolled Population. *Maternal and Child Health Journal* 2013;17:200-207. doi:10.1007/s10995-012-1216-3
- 20 Resende Cardoso P, Lopes Pessoa de Aguiar R, Viana M. Clinical complications in pregnant women with sickle cell disease: prospective study of factors predicting maternal death or near miss. *Revista Brasileira de Hematologia e Hemoterapia* 2014;36:256-263. doi:10.1016/j.bjhh.2014.05.007
- 21 Chang J, Magann E, Novotny S et al. Maternal/Perinatal Outcome in Women with Sickle Cell Disease: A Comparison of Two Time Periods. *Southern Medical Journal* 2018;111:742-745. doi:10.14423/smj.0000000000000900
- 22 Daigavane M, Jena R, Kar T. Perinatal Outcome in Sickle Cell Anemia: A Prospective Study from India. *Hemoglobin* 2013;37:507-515. doi:10.3109/03630269.2013.828301
- 23 Elenga N, Adeline A, Balcaen J et al. Pregnancy in Sickle Cell Disease Is a Very High-Risk Situation: An Observational Study. *Obstetrics and Gynecology International* 2016;2016:1-5. doi:10.1155/2016/9069054
- 24 Ngô C, Kayem G, Habibi A et al. Pregnancy in sickle cell disease: maternal and fetal outcomes in a population receiving prophylactic partial exchange transfusions. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 2010;152:138-142. doi:10.1016/j.ejogrb.2010.05.022
- 25 Omo-Aghoja LO, Okonofua FE (2007). Pregnancy outcome in women with sickle cell- A five-year review. *Niger. Postgrad. Med J.* 14:151-154
- 26 Oteng-Ntim E, Ayensah B, Knight M et al. Pregnancy outcome in patients with sickle cell disease in the UK - a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. *British Journal of Haematology* 2015;169:129-137. doi:10.1111/bjh.13270
- 27 Rajab K, Issa A, Mohammed A et al. Sickle cell disease and pregnancy in Bahrain. *International Journal of Gynecology & Obstetrics* 2006;93:171-175. doi:10.1016/j.ijgo.2006.02.007
- 28 Seaman C, Yabes J, Li J et al. Venous thromboembolism in pregnant women with sickle cell disease: A retrospective database analysis. *Thrombosis Research* 2014;134:1249-1252. doi:10.1016/j.thromres.2014.09.037
- 29 Serjeant G, Loy L, Crowther M et al. Outcome of Pregnancy in Homozygous Sickle Cell Disease. *Obstetrics & Gynecology* 2004;103:1278-1285. doi:10.1097/01.aog.0000127433.23611.54
- 30 Serjeant G, Hambleton I, Thame M. Fecundity and pregnancy outcome in a cohort with sickle cell-haemoglobin C disease followed from birth. *BJOG: An International Journal of Obstetrics & Gynaecology* 2005;112:1308-1314. doi:10.1111/j.1471-0528.2005.00678.x
- 31 Silva-Pinto A, de Oliveira Domingues Ladeira S, Brunetta D et al. Sickle cell disease and pregnancy: analysis of 34 patients followed at the Regional Blood Center of Ribeirão Preto,

Brazil. *Revista Brasileira de Hematologia e Hemoterapia* 2014;36:329-333.  
doi:10.1016/j.bjhh.2014.07.002

32 Soh M, Sankaran S, Chung N et al. Mildly raised tricuspid regurgitant velocity 2.5–3.0 m/s in pregnant women with sickle cell disease is not associated with poor obstetric outcome – An observational cross-sectional study. *Obstetric Medicine* 2016;9:160-163.  
doi:10.1177/1753495x16651529

33 Villers M, Jamison M, Brancazio L et al. Morbidity associated with sickle cell disease in pregnancy. *American Journal of Obstetrics and Gynecology* 2006;195:S106.  
doi:10.1016/j.ajog.2006.10.354

34 Wilson N, Obed S, Gyasi R et al. Pregnancy Outcomes among Patients with Sickle Cell Disease at Korle-Bu Teaching Hospital, Accra, Ghana: Retrospective Cohort Study. *The American Journal of Tropical Medicine and Hygiene* 2012;86:936-942.  
doi:10.4269/ajtmh.2012.11-0625

35 Yu C, Stasiowska E, Stephens A et al. Outcome of pregnancy in sickle cell disease patients attending a combined obstetric and haematology clinic. *Journal of Obstetrics and Gynaecology* 2009;29:512-516. doi:10.1080/01443610903003175

36 Management of Acute Chest Syndrome in Sickle Cell Disease | British Society for Haematology. B-s-h.org.uk. 2020.<https://b-s-h.org.uk/guidelines/guidelines/management-of-acute-chest-syndrome-in-sickle-cell-disease/> (accessed 8 Mar 2020).

37. Asare E, Olayemi E, Boafor T, Dei-Adomakoh Y, Mensah Dip E, Benjamin C et al. Third trimester and early postpartum period of pregnancy have the greatest risk for ACS in women with SCD. *American Journal of Hematology*. 2019;94(12). doi: 10.1002/ajh.25643

38 Malinowski A, Shehata N, D'Souza R et al. Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. *Blood* 2015;126:2424-2435.  
doi:10.1182/blood-2015-06-649319

39 Okusanya B, Oladapo O. Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. *Cochrane Database of Systematic Reviews* Published Online First: 2016. doi:10.1002/14651858.cd010378.pub3

40 Asare E, Olayemi E, Boafor T, Dei-Adomakoh Y, Mensah E, Ghansah H et al. Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low-resource setting. *American Journal of Hematology*. 2017;92(9):872-878. doi: 10.1002/ajh.24790

41 Oppong S, Asare E, Olayemi E, Boafor T, Dei-Adomakoh Y, Swarry-Deen A et al. Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting. *American Journal of Hematology*. 2018;94(2):223-230. doi: 10.1002/ajh.25356

42 Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. *Blood*. 1994. July 15;84(2):643–9

43 Gladwin M, Vichinsky E. Pulmonary Complications of Sickle Cell Disease. *New England Journal of Medicine* 2008;359:2254-2265. doi:10.1056/nejmra0804411

44 RCOG guideline on Reducing the Risk of VTE during pregnancy and the Puerperium. Rcoc.org.uk. 2019.<https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf> (accessed 20 Jun 2019).

45 Weiss B, Zemp L, Seifert B et al. Outcome of Pulmonary Vascular Disease in Pregnancy: A Systematic Overview From 1978 Through 1996. *Journal of the American College of Cardiology* 1998;31:1650-1657. doi:10.1016/s0735-1097(98)00162-4

46 Clapp M, Bernstein S. Preconception Counseling for Women With Cardiac Disease. *Current Treatment Options in Cardiovascular Medicine* 2017;19. doi:10.1007/s11936-017-0565-z

47 Thorne S. Risks of contraception and pregnancy in heart disease. *Heart* 2006;92:1520-1525. doi:10.1136/hrt.2006.095240

48 Lewis, G, ed. *The Confidential Enquiry into Maternal and Child Health, 2000–02 (Why Mothers Die), 2003–05 (Saving Mothers' Lives)*. Reports on Confidential Enquiries into Maternal Deaths in the United Kingdom. London: CEMACH; 2004, 2007.



